Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22382010 | 0.84 | GAA (0.73) | LMNAGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21159809 | 0.84 | GAA (0.73) | LMNAGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21160366 | 0.82 | GAA (0.69) | LMNAGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21159808 | 0.82 | GAA (0.69) | LMNAGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL19924471 | 0.81 | LMNA (0.68) | LMNAGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21160014 | 0.78 | GAA (0.63) | LMNAGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7338962 | 0.77 | GAA (0.62) | LMNAGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5455050 | 0.75 | SMN1; SMN2 (0.88) | LMNAGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21159814 | 0.73 | LMNA (0.56) | LMNAGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5447885 | 0.73 | SMN1; SMN2 (0.84) | LMNAGAARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508474-B1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JAPAN CHEM RES (JP) | 2023-05-17 | — | — | EP | disclosed |
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| WO-2018043399-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | ＪＣＲファーマ株式会社 | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | LMNA 4657/4885GAA 101/4885RAB9A 3427/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | LMNA 4517/4885GAA 58/4885RAB9A 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.